The J-code for SPEVIGO became effective April 1, 2023, according to the Healthcare Common Procedure Coding System.

The U.S. Centers for Medicare & Medicaid Services (CMS) has issued a permanent J-code (J1747) for Boehringer Ingelheim’s SPEVIGO (spesolimab-sbzo) Injection, indicated for the treatment of generalized pustular psoriasis (GPP) flares in adults.

The J-code for SPEVIGO became effective April 1, 2023, according to the Healthcare Common Procedure Coding System (HCPCS). J-codes are permanent, product-specific reimbursement codes used by commercial insurers and government payers to facilitate and streamline billing for Medicare Part B drugs, which cannot be self-administered.

"People living with GPP can experience unpredictable flares and are in need of timely access to novel treatment options," says Claudia Beqaj, Executive Director, Dermatology, Sales and Marketing, Boehringer Ingelheim, in a news release. "We are pleased to receive the permanent J-code for SPEVIGO that aims to enhance and expand market access for those affected by this rare and potentially life-threatening neutrophilic skin disease."

The permanent J-code for SPEVIGO, J1747 (Injection, spesolimab-sbzo, 1 mg), has been published online in the CMS HCPCS Application Summaries and Coding Recommendations, Fourth Quarter, 2022 HCPCS Coding Cycle, here.